[go: up one dir, main page]

ATE362378T1 - Verfahren und zusammensetzungen zur bildung einer schützenden immunantwort gegen malaria - Google Patents

Verfahren und zusammensetzungen zur bildung einer schützenden immunantwort gegen malaria

Info

Publication number
ATE362378T1
ATE362378T1 AT04716571T AT04716571T ATE362378T1 AT E362378 T1 ATE362378 T1 AT E362378T1 AT 04716571 T AT04716571 T AT 04716571T AT 04716571 T AT04716571 T AT 04716571T AT E362378 T1 ATE362378 T1 AT E362378T1
Authority
AT
Austria
Prior art keywords
compositions
methods
forming
immune response
response against
Prior art date
Application number
AT04716571T
Other languages
English (en)
Inventor
Gerd Pluschke
Markus Mueller
John Robinson
Rinaldo Zurbriggen
Annabelle Freund-Renard
Original Assignee
Pevion Biotech Ltd
Swiss Tropical Inst
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pevion Biotech Ltd, Swiss Tropical Inst, Univ Zuerich filed Critical Pevion Biotech Ltd
Application granted granted Critical
Publication of ATE362378T1 publication Critical patent/ATE362378T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04716571T 2003-03-03 2004-03-03 Verfahren und zusammensetzungen zur bildung einer schützenden immunantwort gegen malaria ATE362378T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/379,417 US7198791B2 (en) 2003-03-03 2003-03-03 Compositions and methods for the generation of protective immune responses against malaria

Publications (1)

Publication Number Publication Date
ATE362378T1 true ATE362378T1 (de) 2007-06-15

Family

ID=32926670

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04716571T ATE362378T1 (de) 2003-03-03 2004-03-03 Verfahren und zusammensetzungen zur bildung einer schützenden immunantwort gegen malaria

Country Status (8)

Country Link
US (1) US7198791B2 (de)
EP (1) EP1599225B1 (de)
AT (1) ATE362378T1 (de)
CA (1) CA2545779A1 (de)
DE (1) DE602004006493T2 (de)
DK (1) DK1599225T3 (de)
ES (1) ES2283992T3 (de)
WO (1) WO2004078099A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198791B2 (en) * 2003-03-03 2007-04-03 Pluschke, Gerd Et Al. Compositions and methods for the generation of protective immune responses against malaria
EP1669370A1 (de) * 2004-10-06 2006-06-14 Institut Pasteur Identifikation von Regionen innerhalb des "Apical Membrane Antigen 1" von Parasiten des Stammes der Apicomplexa, welche als Ziel von Vakzinen und Medikamenten in Frage kommen, die über die Analyse der dreidimensionale Struktur ableitbar sind
US20060275777A1 (en) * 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
WO2007099387A1 (en) * 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
EP1938835A1 (de) * 2006-12-29 2008-07-02 Pevion Biotech AG Nichtspezifische immunostimulierende Wirkstoffe
EA025275B1 (ru) 2009-02-06 2016-12-30 Майметикс Корпорейшн Способ, терапевтическая композиция, вакцинная комбинация и набор для терапевтического или профилактического лечения вич
KR101756202B1 (ko) 2009-02-06 2017-07-10 마이메틱스 코포레이션 신규한 ｇｐ41 항원
US20110117120A1 (en) * 2009-11-13 2011-05-19 Martha Sedegah Plasmodium falciparum HLA class I restricted T-cell epitopes
BR112012013581A8 (pt) * 2009-12-05 2017-12-26 Univ Heidelberg Ruprecht Karls vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhantes a ferlinas e outras proteínas que contêm o domínio c2
WO2011128720A1 (en) 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
EP3081575A1 (de) 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium-parasiten-antikörper

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227943A (en) * 1988-02-12 1991-08-27 Saramane Pty Ltd An antigen derived from the neck region of the rhoptries of merozoites and vaccine against plasmodium falciparum
WO1992016616A1 (en) 1991-03-20 1992-10-01 Virogenetics Corporation Malaria recombinant poxvirus vaccine
AU2001277840A1 (en) * 2000-03-07 2002-03-04 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1346049B1 (de) * 2000-12-22 2012-08-01 Stichting Biomedical Primate Research Centre Effiziente expression vom plasmodium apikalmembran-antigen-1 in hefezellen
CN1176945C (zh) * 2001-02-01 2004-11-24 中国人民解放军第二军医大学 疟原虫融合抗原及其制法和用途
EP1423405A4 (de) * 2001-03-26 2005-01-05 Us Army Protein ama-1 aus plasmodium falciparum und verwendungen davon
US7029685B2 (en) * 2001-03-26 2006-04-18 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
US6704957B2 (en) * 2002-07-31 2004-03-16 Steven L. Rhodes Patient support pad for medical imaging equipment
US7198791B2 (en) * 2003-03-03 2007-04-03 Pluschke, Gerd Et Al. Compositions and methods for the generation of protective immune responses against malaria

Also Published As

Publication number Publication date
WO2004078099A3 (en) 2004-10-28
AU2004216833A1 (en) 2004-09-16
DE602004006493D1 (de) 2007-06-28
US7198791B2 (en) 2007-04-03
DK1599225T3 (da) 2007-09-24
DE602004006493T2 (de) 2007-09-13
CA2545779A1 (en) 2004-09-16
EP1599225B1 (de) 2007-05-16
US20040175392A1 (en) 2004-09-09
ES2283992T3 (es) 2007-11-01
WO2004078099A2 (en) 2004-09-16
EP1599225A2 (de) 2005-11-30

Similar Documents

Publication Publication Date Title
ATE318899T1 (de) Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
ATE362378T1 (de) Verfahren und zusammensetzungen zur bildung einer schützenden immunantwort gegen malaria
NO20023829D0 (no) Proteosom influensavaksine
DE60239594D1 (de) Influenza vakzinzusammensetzungen zur intradermaler verabreichung
TW200600108A (en) Microfluidized oil-in-water emulsions and vaccine compositions
WO2005037190A3 (en) Multiplex vaccines
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2004087204A3 (en) Microfluidized oil-in-water emulsions and vaccine compositions
WO2018193063A3 (en) NEW VACCINES AGAINST MALARIA AND ANTIBODIES BINDING PLASMODIUM SPOROZOIDS
WO2006036550A3 (en) Listeria-based and llo-based vaccines
DE602005025342D1 (de) Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
WO2005007673A3 (en) Immunogenic peptides
UA93508C2 (en) Anti-malaria vaccine
WO2017142843A8 (en) Novel antigen for use in malaria vaccine
WO2008054535A3 (en) Novel influenza m2 vaccines
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
Hirunpetcharat et al. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP119) formulated in oil-based Montanides
WO2007016185A3 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
ATE201215T1 (de) Malariapeptide
EP2899203A3 (de) Leishmania impfstoff unter verwendung von sandmücke speichelimmunogen
BR9812976A (pt) Vacina de neospora
TNSN08184A1 (en) Chimeric antigens and vaccines
WO2007020520A3 (en) Antigenic peptides and their use
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
DE602006010061D1 (de) Malariaimpfstoffe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1599225

Country of ref document: EP